AASLD 2024

November 2024, San Diego California

Xinyuan He, MD

An Accurate Race and Ethnic-Specific Novel Index for the Diagnosis of Metabolic Dysfunction-Associated Steatotic Liver Disease

Yu Shi, MD

Updated long-term etiology -specific survival rates of patients with cirrhosis: a 15-year longitudinal real-world study

 

Ashley Fong

Significant differences in the overall and cause specific survival rate across subgroups of patients with cirrhosis

Rui Huang, MD

Impact of metabolic disease on treatment response in chronic hepatitis B patients with nucleos(t)ide analogues therapy: a multicenter REAL-B study

Joanne Liu

Projected changes in tumor characteristics and survival of patients with nonviral hepatocellular carcinoma in the United States: a modeling study based on the SEER-Medicare database

Taotao Yan, MD

Sex Differences in Risk of Adverse Liver and Non-liver Outcomes in Metabolic Dysfunction-associated Steatotic Liv er Disease: a U.S. Population-based Cohort Study

 

Taotao Yan, MD

Differential Mortality Risk by Age in Males and Females with Steatotic Liver Disease.

Xinrong "Winnie" Zhang, MD

Impact of Laparoscopic surgery versus open surgery on long-term outcomes and healthcare utilization in patients with metabolic dysfunction-associated steatotic liver disease and severe obesity

Michael Le

Late Diagnosis of Chronic Hepatitis B is Associated with Increased Liver-Related Complications - A Population-Based, Retrospective Cohort Study

Alex Do

The prevalence and natural history of subtypes of indeterminate phase chronic hepatitis B: results of the international real-b cohort.

Poster of Distinction

Jie Li, MD

 

Global Outcome and Prevalence of CHB patients with indeterminate phase: A Systematic review and Meta-Analysis of 35 studies and 27,529 patients.

AASLD Nguyen Lab Luncheon